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Although the annual mortality rate for end-stage renal disease (ESRD) is decreasing, likely
due to an increase in kidney transplantation rate, the survival probability for ESRD patients
from day one of dialysis has not changed, and is still poor with a 5-year survival rate of
approximately 34%.This is contributed to by a high prevalence of cardiovascular disease,
which is the leading cause of death in ESRD patients. In order to improve survival out-
comes, patients at high risk of cardiovascular related mortality need to be identiﬁed. Heart
rate variability (HRV), baroreceptor sensitivity, and baroreceptor reﬂex effectiveness index
canbeusedtoassessheartratecontrolandmaypredictcardiovascularmortality.Thispaper
will discuss how HRV, baroreceptor sensitivity, and baroreceptor reﬂex effectiveness index
are altered in renal disease and the utility of these indices as markers of cardiac risk in this
patient population.
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INTRODUCTION
Cardiovascular disease is highly prevalent chronic kidney disease
(CKD) and end-stage renal disease (ESRD) patients, and occurs
due to the development of vasculopathies, e.g., atherosclerosis or
arteriosclerosis, or cardiomyopathy, resulting in ischemic heart
disease or heart failure (Parfrey and Foley, 1999; Shamseddin
and Parfrey, 2011). The high incidence of cardiovascular dis-
ease in CKD/ESRD patients is due to a greater prevalence of
traditional cardiovascular risk factors, e.g., hypertension, hyper-
lipidemia, and diabetes, and risk factors associated with a chronic
uremic state, e.g., volume overload, anemia, and oxidative stress
(Parfrey and Foley, 1999). Consequently, cardiovascular disease
is the leading cause of death in ESRD patients, accounting for
∼40% of deaths in dialysis patients (U.S. Renal Data System,
2011).
Sudden cardiac death is the major cause of cardiac mortal-
ity in ESRD (Herzog, 2003; U.S. Renal Data System, 2011). The
incidence of sudden cardiac death increases as the stage of kid-
ney disease increases. In a retrospective study of renal disease
patientswithcoronaryarterydisease,theincidenceof suddencar-
diac death was 3.8 events per 1000 patient-years in patients with
anestimatedglomerularﬁltrationrate(eGFR)≥60ml/min,7.3in
patients with an eGFR between 15–59ml/min,and 24.2 in dialysis
patients (Pun et al., 2009). The prognosis for ESRD patients who
have been resuscitated following a cardiac arrest is abysmal, with
60% of patients dying in the ﬁrst 48-h (Karnik et al., 2001), and
a 30-day and 1-year survival rate of only 32 and 15%,respectively
(Herzog, 2003). Nevertheless, despite these disturbing statistics,
the high cardiovascular mortality rate in ESRD patients may be
reduced, as the use of angiotensin converting enzyme inhibitors
or angiotensin receptor blockers, independent of any antihyper-
tensive effect, is associated with a lower risk of mortality (Efrati
et al.,2002; Fang et al.,2008). In order to reduce the cardiac mor-
tality rate in ESRD,however,CKD or ESRD patients at a high risk
of cardiac death need to be identiﬁed early, to allow appropriate
clinical intervention.
Abnormalities in autonomic function, namely sympathetic
overdrive and parasympathetic insufﬁciency, play a key role in
the susceptibility to sudden cardiac death (Schwartz and Stone,
1980; Schwartz et al., 1988, 1992). There is now an overwhelming
amount of evidence showing the involvement of the autonomic
nervous system in the genesis of cardiovascular disease in CKD.
This includes sympathetic overactivity,as muscle (Converse et al.,
1992; Hausberg et al., 2002; Klein et al., 2003), but not skin (Park
et al., 2008; Grassi et al., 2009), sympathetic nerve activity is ele-
vated. The increase in muscle sympathetic nerve activity occurs
early in the disease progression (Grassi et al., 2011) and likely
increases the risk of mortality, as elevated plasma noradrenaline
levels are associated with both an increased risk of all-cause mor-
tality and cardiovascular events in ESRD patients without heart
failure (Zoccali et al., 2002). Conversely, parasympathetic nerve
activityisreduced,evidencedbyreducedheartrate(HR)responses
to deep breathing, valsalva maneuver, and standing up (Agarwal
et al., 1991; Sahin et al., 2006). This sympatho-vagal imbalance
undoubtedly contributes to the increased risk of sudden cardiac
death in CKD/ESRD.
Heart rate variability (HRV) and baroreceptor reﬂex sensitiv-
ity (BRS) can be used to examine autonomic regulation of HR.
In myocardial infarction survivors, reduced HRV and BRS have
been shown to be highly predictive of an increased risk of cardiac
mortality (La Rovere et al., 1998, 2001). This review will discuss
how HRV,BRS,and an additional measure of baroreﬂex function,
baroreceptoreffectivenessindex(BEI),arealteredinrenaldisease,
and their utility in predicting cardiac risk in ESRD patients.
HEART RATE VARIABILITY
Heart rate variability reﬂects the ability of the sinoatrial node to
adaptively alter HR in response to sympathetic and parasympa-
thetic inputs, respiration, circadian rhythm, and hormonal and
thermoregulatoryinﬂuences(Stauss,2003).Inmanydiseasestates,
the sinoatrial node is less able to alter HR, and instead the heart
beats like a metronome. Irrespective of the underlying cause, a
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reduction in HRV may predict sudden cardiac death (Molgaard
et al.,1991; La Rovere et al.,2003; Kataoka et al.,2004).
Heart rate variability can be assessed in a variety of ways:time-
domain analysis (statistical or geometrical), frequency-domain
analysis, or non-linear methods (Task Force of the ESC and
NASPE, 1996). Statistical time- and frequency-domain analyses
of HRV are the most commonly used methods. Statistical time-
domainparametersofHRVincludeSDofallnormalR–Rintervals
(SDNN), SD of the average R–R interval in all 5-min segments
(SDANN),square root of the mean squared differences of succes-
sive R–R intervals (RMSDD),and the proportion of adjacent R–R
intervals that are more than 50ms apart (pNN50). Frequency-
domain indices of HRV include total (TP), high frequency (HF),
low frequency (LF), and very low frequency (VLF) power. Total
power and SDNN correlate, reﬂecting overall HRV. HF power,
RMSDD, and pNN50 are analogous and reﬂect vagal and respi-
ratory mediated changes in HR. LF power reﬂects the capacity
of both the parasympathetic and sympathetic nervous systems to
alter HR, and cardiovascular reﬂexes, such as the, baroreceptor
reﬂex to buffer changes in HR.VLF and SDANN reﬂect long-term
changes in HR (Task Force of the ESC and NASPE, 1996; Zaza
and Lombardi, 2001; Guzik et al., 2007). A summary of how the
various HRV indices are altered in CKD/ESRD is presented in
Table 1.
TheRenalResearchInstitute-CKDstudy,afourcenterprospec-
tive cohort study of adults with moderate to severe CKD (stages
3–5), demonstrated that HRV decreased as renal disease severity
increased. In this study, SDNN, SDANN, VLF, and LF:HF power
was lower in stage 5 non-dialysis CKD patients compared with
stage3and4CKDpatients(Chandraetal.,2011).Furthermore,in
type 1 diabetics with overt nephropathy,SDNN,RMSSD,pNN50,
SDANN, and LF power are positively related to creatinine clear-
ance, such that a decline in creatinine clearance is associated with
a diminution of HRV (Burger et al., 2002). Thus, the progressive
decline in renal function that occurs in renal disease alters auto-
nomicandlong-termregulationof HR,resultinginareductionin
HRV.
Few studies have examined the difference in HRV parameters
between stage 4/5 non-dialysis CKD and dialysis patients. Those
that have demonstrate no difference in the spectral indices (i.e.,
TP, HF, and LF) between stage 4/5 non-dialysis CKD and dialysis
patients(Mylonopoulouetal.,2010;Roumeliotietal.,2010),while
time-domain indices (e.g., SDNN and SDANN) may increase in
dialysis patients (Mylonopoulou et al., 2010). The lack of differ-
enceinspectralHRVindicesmayindicatethattheinhibitoryeffect
of renal disease on HRV has reached maximal levels prior to the
need for renal replacement therapy.
Several co-variates affect HRV estimates in ESRD/CKD
patients, the most signiﬁcant of which is diabetes. Regardless
of disease stage, diabetic CKD patients have lower HRV indices
(Yamanaka et al.,2005; Mylonopoulou et al.,2010; Chandra et al.,
2011).Thecombinationof renaldiseaseanddiabeteshasagreater
inhibitory effect on HRV than the presence of renal disease or
diabetesalone,withnon-diabeticESRDanddiabeticpatientshav-
ing similar HRV estimates (Mylonopoulou et al., 2010). The only
exception is HF power, which is comparable in diabetic and non-
diabetic ESRD patients (Mylonopoulou et al.,2010). High resting
HR, older age, elevated serum phosphorus levels, anemia, high
cholesterollevels,increasedleftventricularmassindex,and/oruse
of beta-blockers are also associated with reduced HRV in CKD
and ESRD (Steinberg et al., 1998; Furuland et al., 2008; Chandra
et al.,2011).
One of the hypothesized causes for autonomic dysfunction,
which can result in reduced HRV and an increased risk of car-
diac mortality (La Rovere et al., 1998), in ESRD is a uremia
driven excitation of the renal afferent nerves. Accordingly, muscle
sympatheticnerveactivityislowerinnephrectomizedversusnon-
nephrectomized ESRD patients (Converse et al., 1992). Further-
more, conversion from conventional to nocturnal hemodialysis,
which allows for a more aggressive correction of uremia, reduces
plasma noradrenaline levels (Chan et al., 2003). Uremic excita-
tion of renal afferents may also underlie reduced HRV. Acutely,
hemodialysis increases SDNN, SDANN and reduces the ratio of
LF to HF power (Giordano et al., 2001; Tong and Hou, 2007;
Mylonopoulou et al., 2010; Celik et al., 2011); whereas, conver-
sion from chronic to nocturnal hemodialysis increases HF power
and normalizes LF to HF ratio (Chan et al., 2004). Following
renal transplantation, there is an eventual improvement in HRV.
At 1month post-transplantation, HRV parameters are similar to
pre-transplantation levels (Yang et al., 2010), while from 5 to
12months post-transplantation, LF, HF, TP, and SDNN are sim-
ilar to healthy control levels (Yildiz et al., 1998; Rubinger et al.,
2009;Yang et al., 2010). Nevertheless, such improvements are not
alwaysreported(Kurataetal.,2004;Parisottoetal.,2008);whether
this reﬂects an insufﬁcient post-surgical recovery time (recovery
time 1–4+months) or other causes for reduced HRV in ESRD is
unknown.
The Renal Research Institute-CKD study concluded that a low
LF to HF ratio was associated with a higher risk of progression to
ESRD(Chandraetal.,2011)andtheAtherosclerosisRiskinCom-
munities study highlighted the association between low LF and
HF power and the subsequent development of renal impairment,
even after correction for classical risk factors such as diabetes,
hypertension, and low baseline renal function (Brotman et al.,
2010). On the basis of this alone, reduced HRV values are pre-
dictive of a greater risk of mortality, whether cardiac related or
not, due to a higher risk of developing ESRD. Reduced HRV can
also predict an increased risk of cardiac mortality, with retro-
spective evidence existing that ESRD or CKD patients that died
of coronary artery disease, peripheral artery disease, congestive
heart failure, acute myocardial infarction, or a cardiac arrest, had
reduced HRV, notably low VLF, LF, and LF to HF ratio values,
compared with survivors (Fukuta et al., 2003a; Chandra et al.,
2011). Interestingly, ultra LF power, a rarely reported frequency-
domain parameter that reﬂects circadian rhythm changes in HR
(Stauss, 2003), is a highly sensitive parameter in predicting car-
diacrelateddeaths(e.g.,acutemyocardialinfarction,heartfailure,
sudden cardiac death) in ESRD patients (Hayano et al., 1999;
Fukuta et al., 2003a,b), with values less than 8.7ms2, predictive
of sudden cardiac death (Hayano et al., 1999). Time-domain
estimates of HRV are also predictive of cardiac mortality, with
SDNN estimates less than 50ms reﬂective of a greater risk of
sudden cardiac death (Hathaway et al., 1998; Hayano et al.,
1999).
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Table 1 | Heart rate variability parameters in end-stage renal disease patients.
Reference Patient cohort HRV parameters
in ESRD patients
Comments
Celik et al. (2011) 31 ESRD patients on HD therapy
31 Healthy controls
Reduced SDNN
Reduced SDANN
Reduced RMSSD
Comparisons made with controls only following dialy-
sis therapy
Showed that HRV parameters improved following HD
therapy
Yang et al. (2010) 14 ESRD patients on HD therapy
14 Healthy controls
Reduced total power
Reduced LF power
Reduced HF power
Showed that all HRV parameters had improved by 6
months following renal transplantation
Giordano et al. (2001) 20 ESRD patients (9 diabetic) on HD
therapy
10 Healthy controls
Reduced total power
Increased LF (nu)
Reduced HF (nu)
Results shown here only include non-diabetic ESRD
patients
Total power and HF power lower in diabetic ESRD
patients
LF power higher in diabetic ESRD patients
Kurata et al. (2004) 13 ESRD patients on HD patients
10 Healthy controls
Reduced SDNN
Reduced rMSSD
Reduced LF power
Reduced HF power
Renal transplantation had no effect on HRV
parameters measured
Yang et al. (2010) 14 ESRD patients on HD that received
renal transplants
14 Healthy controls
Reduced total power
Reduced LF power
Reduced HF power
Renal transplant normalized reduction in total power
Renal transplant increased but did not normalize, LF
and HF power
Fukuta et al. (2003a) 120 ESRD patients on HD therapy
62 Healthy controls
Reduced SDNN
Reduced total power
Reduced ULF
Reduced VLF
Reduced LF power
Reduced HF power
ReducedVLF and ULF were predictive of cardiac
death
Rubinger et al. (2009) 52 ESRD patients on chronic HD therapy
44 ESRD patients with renal transplants
41 Healthy controls
Reduced LF power
Reduced HF power
LF power corrected 1 year following renal transplant
HF power not altered 1 year following renal transplant
Furuland et al. (2008) 16 Stage 4 CKD patients
16 Healthy controls
Reduced SDNN
Reduced SDANN
No change in rMSSD
No change in pNN50
Reduced total power
Reduced LF power
No change in HF power
Hemoglobin normalization corrected reduction in LF
and total power
Hemoglobin normalization did not affect time domain
estimates of HRV
Studinger et al. (2006) 14 Juvenille ESRD patients on HD
14 Juvenille renal transplant recipients
14 Healthy controls
Reduced RMSSD
Reduced LF power
No change in HF power
Renal transplant recipients showed no difference in
RMSSD or HF power
Steinberg et al. (1998) 66 ESRD patients (26 diabetic) on HD
33 Healthy controls
Reduced LF power
Reduced HF power
Diabetes was a major determinant for reduced LF
power
Age was a borderline signiﬁcant determinant for
reduced HF power
Yamanaka et al. (2005) 27 ESRD patients (13 diabetic) on HD
46 Healthy controls
Reduced LF power
Reduced HF power
LF and HF power was reduced further in diabetic
ESRD patients
BAROREFLEX SENSITIVITY AND EFFECTIVENESS
In comparisons to the numerous studies examining HRV in
CKD/ESRD patients, relatively little is known regarding barore-
ceptor reﬂex control of HR. This may reﬂect the methodology
required to investigate baroreceptor function, which requires a
blood pressure recording as opposed to the simple acquisition of
an ECG signal. It is not an indication, however, that assessing
baroreceptor reﬂex function is not a useful marker of cardiac risk.
On the contrary, reduced baroreceptor reﬂex control of HR has
been established as a strong predictor of cardiac mortality follow-
ing myocardial infarction (La Rovere et al., 1998), and in heart
failure patients (Mortara and Tavazzi,1996).
Baroreceptor reﬂex control of HR can be assessed by exam-
ining the sensitivity of the reﬂex (BRS), i.e., the ability of the
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baroreceptor reﬂex to produce reﬂex bradycardia or tachycar-
dia. Alternatively, although not as utilized, the effectiveness of the
baroreceptor reﬂex (BEI), i.e., how often the baroreceptor reﬂex
produces a change in HR in response to a perturbation in blood
pressure,can be examined (Di Rienzo et al.,2001). High BRS and
BEI scores are reﬂective of healthy baroreceptor reﬂex control of
HR.
Baroreceptor reﬂex control of HR, as examined by BRS (Pick-
ering et al., 1972; Lazarus et al., 1973; Agarwal et al., 1991; Ger-
hardt et al., 1999; Gao et al., 2005; Studinger et al., 2006) and
BEI (Johansson et al., 2005, 2007), is impaired in renal disease
patients and may worsen as the disease severity increases. To date,
only two studies (Bavanandan et al., 2005; Lacy et al., 2006)h a v e
examined BRS in moderate to severe non-diabetic CKD patients.
Both studies showed that BRS was positively correlated to GFR,
implying that BRS reduced as renal disease severity increases
(i.e., GFR decreased). Furthermore, Lacy et al. (2006) demon-
stratedthatBRSwaslowerinstage4CKDpatientscomparedwith
stage 3 CKD patients. However, neither study included a control
group. Therefore, it is still unknown at which point in the disease
process baroreceptor reﬂex control of HR alters. In addition to
theimpactof worseningrenalfunction,additionalco-morbidities
mayhaveadditivenegativeeffectsonbaroreceptorreﬂexfunction,
with greater reductions in BRS and BEI noted in diabetic versus
non-diabetic ESRD patients (Johansson et al., 2005).
ThedeclineinBRSandBEIinESRDcanbereversedasconver-
sion from chronic to nocturnal hemodialysis increases BRS and
BEI (Chan et al., 2005, 2008). This is hypothesized to result from
an increase in arterial compliance as the improvement in BRS that
follows conversion to nocturnal hemodialysis is positively corre-
lated with an increase in stroke volume to pulse pressure ratio
(Chan et al.,2005). Furthermore,following renal transplantation,
BRS and BEI is increased to control levels (Studinger et al., 2006;
Rubinger et al., 2009).
The exact cause(s) of impaired baroreceptor reﬂex function in
ESRD is unknown, but may relate, in part, to an inability for the
baroreceptors to sense changes in blood pressure. This could arise
fromvascularstiffnessintheaorticarchandcarotidsinus,theori-
gin of baroreceptor afferents, as BRS is negatively correlated with
increased carotid artery stiffness (Studinger et al., 2006) and an
increase in vascular calciﬁcation, albeit in the superﬁcial femoral
artery, in dialysis patients (Chesterton et al., 2005). Alternatively,
itcouldbeduetoabnormalcentralprocessingof thebaroreceptor
reﬂex or an inability for the cardiac vagal or sympathetic efferents
to produce effective changes in HR.
Despite the limited number of studies examining BRS and
BEI in ESRD patients, a reduction in these parameters confers
an increased risk of mortality. Reduced BEI is an independent
predictor of all-cause mortality, while reduced BRS, an indepen-
dent predictor of sudden cardiac death (Johansson et al., 2007).
The impact of reduced BRS in ESRD is not limited to a poten-
tial predisposition to life threatening arrhythmias. A reduction
in BRS may also contribute to hemodialysis related hypoten-
sion,a signiﬁcant cause of mortality in hemodialysis patients,due
to an inability to counteract dialysis induced volume depletion
(Heber et al., 1989; Chesterton et al., 2010). Further studies are
required, however, to verify and strengthen the use of BRS as
a predictive marker of an increased risk of cardiac mortality in
CKD/ESRD.
CONCLUSION
Heart rate variability,BRS,and BEI are reduced in ESRD patients.
These three parameters convey different information regarding
cardiovascular health and may provide independent indications
of a greater risk of cardiovascular mortality. Although individ-
ual HRV parameters are inconsistently reported as reduced in
CKD/ESRD patients,a simple estimation of overall HRV (SDNN)
can easily identify CKD/ESRD patients at risk of sudden cardiac
death.Comparativelylittleisknownregardingbaroreceptorreﬂex
function in CKD. Nevertheless, BRS and BEI have been shown
to predict sudden cardiac death and all-cause mortality in ESRD
patients respectively.
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